Taken together, the encouraging safety and efficacy data from early phase anti-GPRC5D CAR T trials have propelled GPRC5D forward as the next promising therapeutic target moving closer to regulatory approval in myeloma. Here, GPRC5D is linked to plasma cell myeloma.